Sawai Group Holdings Co., Ltd.
Saway Group Holdings Co., Ltd. 2027 Fiscal Year Q1 Consolidated Financial Results Summary
For the first quarter of the 2027 fiscal year, consolidated net sales were 51,622 million yen (YoY +4.3%), operating income was 4,953 million yen (△29.0% YoY), and net income attributable to owners of the parent was 2,429 million yen (△50.3% YoY). Progress against the medium-term plan Beyond 2027, strengthening of the generic drug business, and the impact of divestment of non-core US operations continued. The full-year plan foresees net sales of 208,400 million yen and operating income of 27,200 million yen.
Key Figures
- Sales revenue: 51,622百万円
- Operating income: 4,953百万円
- Net income attributable to owners of the parent: 2,429百万円
AI要約
Performance overview
As an IFRS-applying company, quarterly revenue increased, but operating income and net income fell below the prior year. The US business is excluded from continuing operations due to capital relationships, and indicators for continuing and discontinued operations are disclosed separately. Core operating income is an indicator excluding non-recurring factors and decreased YoY. Under the Beyond 2027 medium-term plan, emphasis is placed on stable supply of generic medicines and business sustainability.
Outlook and capital policy
The full-year forecast is net sales of 208,400 million yen, core operating income of 29,600 million yen, operating income of 27,200 million yen, and net income attributable to owners of the parent of 18,600 million yen. While considering the impact of the US non-core asset divestiture, the company will continue to strengthen its generics supply stability and production capacity, advancing the organizational framework through 2027.
Listed Company Name Saway Group Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR
